| (+)-(S)-1-[3-(Dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofurancarbonitrile oxalate |
| (+)-(S)-Citalopram oxalate |
| (1S)-1-[3-(Dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofurancarbonitrile Ethanedioate |
| (1S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile; oxalic acid |
| (1S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile;oxalic acid |
| (1S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-isobenzofuran-5-carbonitrile; oxalic acid |
| (S)-(+)-Citalopram Oxalate |
| (S)-(+)Citalopram oxalate |
| (S)-1-(3-(Dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile oxalate |
| (S)-1-[3-(Dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile Oxalate |
| (S)-Citalopram Oxalate |
| 219861-08-2 |
| 5-Isobenzofurancarbonitrile, 1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydro-, (1S)-, ethanedioate (1:1) |
| 5U85DBW7LO |
| 861E082 |
| AB0012102 |
| AC-6770 |
| AC1L3TGZ |
| AK138215 |
| AKOS016340275 |
| AN-13009 |
| AN-9671 |
| AOB4715 |
| AX8019428 |
| BG0433 |
| C22H23FN2O5 |
| CAS-219861-08-2 |
| cc-372 |
| CCG-39559 |
| CHEMBL1200322 |
| Cipralex |
| Citalopram Oxalate |
| CPD000469191 |
| CS-2054 |
| D02567 |
| DSSTox_CID_26003 |
| DSSTox_GSID_46003 |
| DSSTox_RID_81282 |
| DTXSID1046003 |
| E0958 |
| Entact |
| Escitalopram (oxalate) |
| Escitalopram for system suitability, EuropePharmacopoeia (EP) Reference Standard |
| Escitalopram oxalate (JAN/USAN) |
| Escitalopram oxalate [USAN:USP] |
| Escitalopram oxalate [USAN] |
| escitalopram oxalate inn |
| Escitalopram oxalate, >=98% (HPLC), powder |
| Escitalopram oxalate, EuropePharmacopoeia (EP) Reference Standard |
| Escitalopram oxalate, United States Pharmacopeia (USP) Reference Standard |
| FT-0650410 |
| Gaudium |
| HMS2051D11 |
| HMS2231M16 |
| HMS3370I17 |
| HMS3393D11 |
| HY-14258A |
| J90016 |
| KS-1263 |
| KTGRHKOEFSJQNS-BDQAORGHSA-N |
| Lexapro |
| Lexapro (TN) |
| LS-183519 |
| Lu 26-054-0 |
| Lu-26-054-0 |
| LU-260540 |
| MFCD06407826 |
| MLD-55 |
| MLS001401408 |
| MolPort-003-666-613 |
| NC00194 |
| NCGC00095903-01 |
| NCGC00178555-02 |
| NSC-758934 |
| NSC758934 |
| Pharmakon1600-01505216 |
| S-(+)-1-(3-(Dimethylamino)propyl)-1-(p-fluorophenyl)-5-phthalancarbonitrile oxalate |
| S-(+)-1-[3-(Dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofurancarbonitrile oxalate |
| S-(+)-5-Isobenzofurancarbonitrile, 1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydro-, oxalate |
| S-(+)-Citalopram oxalate |
| SAM001246668 |
| SCHEMBL35123 |
| SMR000469191 |
| SPECTRUM1505216 |
| ST24046691 |
| TL8001823 |
| Tox21_111535 |
| Tox21_111535_1 |
| UNII-5U85DBW7LO |
| UNII-B5RDX2419X component KTGRHKOEFSJQNS-BDQAORGHSA-N |
